Donoghue Forlines’s DexCom DXCM Stock Holding History

Donoghue Forlines’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-38,524	Closed	-$2.42M	–	130
2026 Q1	$2.42M	Buy	+38,524	New	+$2.68M	0.67%	52
2023 Q3	–	Sell	-3,893	Closed	-$500K	–	235
2023 Q2	$500K	Buy	+3,893	New	+$471K	0.16%	126

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Donoghue Forlines's DXCM Position: Q2 2026 in Review

Donoghue Forlines sold out of DexCom (DXCM) in Q2 2026, closing a stake of 38,524 shares — an estimated $2.42M sold.

Donoghue Forlines first reported a position in DXCM in Q2 2023 and held it in 2 quarters. The position peaked at $2.42M in Q1 2026. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

Donoghue Forlines reported no remaining DexCom position as of Q2 2026 after selling out during the quarter.
Donoghue Forlines sold 38,524 DexCom shares in Q2 2026, an estimated $2.42M.
Donoghue Forlines first reported a position in DexCom in Q2 2023 and held it in 2 quarters.
Donoghue Forlines's DexCom position peaked at $2.42M in Q1 2026.
973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Donoghue Forlines's 13F filing for Q2 2026, filed 7 Aug 2026.